Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Cash Flow

v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net loss $ (9,091) $ (6,620)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 27 13
Stock-based compensation 825 487
Deferred compensation - related party 0 62
Change in fair value of warrant liability (1,614) 2,753
Gain in settlement of liability 0 (149)
Gain from expiration of warrants 0 (1,238)
Loss on foreign currency transactions 23 0
Other 0 (9)
Changes in operating assets and liabilities:    
Prepaid expenses (172) (518)
Accounts payable (25) 517
Accrued expenses and other liabilities 923 (232)
Other long-term liabilities 11 0
Net cash used in operating activities (9,093) (4,934)
Cash flows from investing activities:    
Purchase of fixed assets (303) (12)
Net cash used in investing activities (303) (12)
Cash flows from financing activities:    
Proceeds from exercise of warrants 15 3,808
Proceeds from sale of common stock units, net of cash stock issuance costs 10,269 4,867
Net Cash Provided by Financing Activities 10,284 8,675
Effect of exchange rate changes on cash and cash equivalents (2) 0
Net change in cash and cash equivalents 886 3,729
Cash and cash equivalents, at beginning of period 7,714 5,007
Cash and cash equivalents, at end of period 8,600 8,736
Supplemental disclosures of cash flow information:    
Cash paid for interest 3 2
Cash paid for taxes 20 0
Supplemental disclosure of non-cash investing and financing activities:    
Purchases of property and equipment in accounts payable and accrued liabilities 136 0
Leasehold improvements paid by landlord 82 0
Common stock issued for conversion of debt 0 302
Common stock issued for services provided 0 89
Warrants exercised – not yet paid $ 0 $ 34

Source